TIO Associated with Hyperparathyroidism: A Rarity, a Rule, or a Novel HPT-PMT Syndrome—A Case Study with Literature Review

Table 1

Laboratory evaluation.

Measure	Ref	2011^a	2012^a	2013^a	2014^a	2015^a	2016^a	2017^a	2018^b	2019^b	2020^b
PTH, pg/mL	14–72	114.1	—	110.6	247.6	220.4	—	274.4	—	—	126.3
Ca, mg/dL	8.5–10.1	9.2	8.9	9.2	9.5	9.0	8.3	9.8	10.1	9.9	10.6
PO4, mg/dL	2.5–4.9	1.6	1.6	1.0	1.7	0.9	2.3	1.7	3.0	3.0	2.6
Vit D 25(OH)D, ng/mL	30–100	16	—	46	31	32	—	30	30	24	37
Vit D 1,25(OH)2, pg/mL	18–72	9	—	27	-	29	—	27	70	37	-
ALP, IU/L	44–174	283	—	252	243	262	—	103	71	71	71
FGF23, RU/mL	0–180	—	—	291	-	-	—	1330	160	174	174
eGFR, mL/min/1.73 m^2	>60	58	—	85	90	75	66	64	66	66	61
FeP	<20%	—	—	44%	—	—	—	—	—	—	—

ALP, alkaline phosphatase; Ca, calcium; eGFR, estimated glomerular filtration rate; FeP, fractional excretion of phosphate; FGF, fibroblast growth factor; PO₄, phosphate; PTH, parathyroid hormone; Ref, reference. ^aPrior to tumor resection. ^bFollowing tumor resection.